Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)

Ischemic Stroke Clinical Trial

— CE-5S  

Official title:

Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03290053
• Other study ID #: CE-5S
• Status: Terminated
• Phase: Phase 3
• Start date: November 28, 2017
• Est. completion date: April 18, 2018

Study information

• Verified date: November 2017
• Source: Umeå University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients with acute ischemic stroke in anterior circulation within 4,5 hours of symptom onset, has a bone window and Trombolysis In Brain Ischemia (TIBI) <=4 in a relevant artery eligible. Both patients receiving thrombolysis and those who do not due to contraindications such as anticoagulation or recent surgery are enrolled, but into different study arms (CE-5S A for thrombolysis and B for non-thrombolysis); the decision to treat with thrombolysis or not is done according to clinical routine.

All included patients are randomized to receive transcranial ultrasound and SonoVue-infusion or sham-ultrasound and placebo; i.e. in CE-5S A, contrast enhanced sonothrombolysis is compared to thrombolysis and in CE-5S B, contrast enhanced sonolysis is compared with conservative management.

Main outcome is improvement in National Institute of Health Stroke Scale (NIHSS) at 24 hours compared to baseline. Main safety outcome is symptomatic intracerebral haemorrhage.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: April 18, 2018
• Est. primary completion date: April 18, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patients =18 years with acute ischaemic stroke in the anterior circulation, who has given written consent for his/her participation to the study.

• Remaining neurological deficit that is =1 NIHSS points, sufficient to warrant treatment with tPA (not taking possible contraindications into account) and is severe enough that possible improvement is clearly analysable

• Treatment <4½ hours of symptom onset or of waking up in the morning with symptoms

• Sufficient bone window for acceptable or better acquisition of flow information with ultrasound with TIBI = 4 in the symptomatic artery

• In cases with women of Childbearing Capacity (WOCBC): Only if willing to comply with effective contraception methods during the course of the trial. Acceptable methods are such as oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double-barrier methods (for example, condom and spermicide), intrauterine device (IUD), hormonal IUD

Exclusion Criteria:

• Patients with premorbid modified Rankin Scale (mRS) score =3;

• Patients for whom a complete NIHSS cannot be obtained;

• Hemiplegic migraine with no arterial occlusion on baseline Computed Tomography of brain (CT);

• Seizure at stroke onset and no visible occlusion on baseline CT;

• Intracranial haemorrhage on baseline CT;

• Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is normal;

• Large areas of hypodense ischaemic changes on baseline CT;

• Pregnancy or breast-feeding, pericarditis; sepsis; any other serious medical illness likely to interact with treatment; confounding pre-existent neurological or psychiatric disease; unlikely to complete follow-up; any investigational drug <14 days;

• Inability to provide informed consent sufficiently clearly that the study physician can be convinced that informed consent has been given by the patient - such as severe aphasia or coma.

Specific sonothrombolysis exclusion criteria

• known hypersensitivity/allergy to SonoVue;

• recent or unstable coronary ischemia or resting angina <7 days;

• acute cardiac insufficiency, cardiac insufficiency class III/IV; serious cardiac arrhythmias;

• any right-left-shunt; severe pulmonary hypertension; uncontrolled hypertension;

• moderate to severe Chronic Obstructive Pulmonary Disease (COPD; baseline O2 saturation <80%);

• acute respiratory distress syndrome (ARDS);

Related Conditions & MeSH terms

• Ischemic Stroke
• Stroke

Intervention

Drug:
• SonoVue
SonoVue-infusion over 1 hour
• Sodium chloride
Placebo

Procedure:
• Transcranial Ultrasound
Transcranial ultrasound aimed at the blockage
• Sham Transcranial Ultrasound
Placebo - machine is attached, but not active

Locations

Country	Name	City	State
Sweden	University Hospital	Umeå	Västerbotten

Sponsors (1)

Lead Sponsor	Collaborator
Umeå University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Early clinical Outcome defined as change in NIHSS at 24 hours.	Change in National NIHSS at 24 hours. Defined reaching of primary endpoint is post-treatment 0 Points and/or improves with >=4 Points compared to pre-treatment.	24 hours
Secondary	Safety: Symptomatic Cerebral Hemorrhage (sICH)	Assessed with routine post-treatment CT head and requires an accompanied >=4 Points worsening on NIHSS.	24-36 hours
Secondary	Long term outcome defined as residual handicap at Three months	90-days modified Rankin Scale (mRS) reaching 0-1.	90 days